Accelerated conformal radiotherapy for stage I non-small cell lung cancer (NSCLC) in patients with pulmonary dysfunction: A CALGB phase I study

被引：0
|
作者：
Bogart, J.
Watson, D.
Seagren, S.
Blackstock, A. W.
Wang, X.
Lenox, R.
Vokes, E.
Turrisi, A. T.
Green, M. R.
机构：
[1] SUNY Upstate Med Univ, Syracuse, NY 13210 USA
[2] CALGB Stat Ctr, Durham, NC USA
[3] Univ Calif San Diego, San Diego, CA USA
[4] Wake Forest Sch Med, Winston Salem, NC USA
[5] Univ Chicago, Chicago, IL 60637 USA
[6] Wayne State Univ, Detroit, MI USA
[7] Care Alliance Roper Hosp, Charleston, SC USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7556
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Hypofractionated radiotherapy as definitive treatment of stage I non-small cell lung cancer in older patients
    Ahmad, E.
    Sandhu, A. P.
    Fuster, M.
    Messer, K.
    Pu, M.
    Nobiensky, P.
    Bazhenova, L.
    Seagren, S.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2008, 72 (01): : S478 - S478
  • [42] Hypofractionated Radiotherapy as Definitive Treatment of Stage I Non-Small Cell Lung Cancer in Older Patients
    Ahmad, Ehatsham
    Sandhu, Ajay P.
    Fuster, Mark M.
    Messer, Karen
    Pu, Minya
    Nobiensky, Polly
    Bazhenova, Lyudmila
    Seagren, Stephen
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2011, 34 (03): : 254 - 258
  • [43] Pulmonary Function Changes After Stereotactic Ablative Radiotherapy In 201 Patients With Stage I Non-small Cell Lung Cancer
    Senan, S.
    Phernambucq, E. C. J.
    van de Ven, P. M.
    Groepenhoff, H.
    Postmus, P. E.
    Slotman, B. J.
    Smit, E. F.
    Lagerwaard, F. J.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011, 81 (02): : S579 - S579
  • [44] A phase I trial of gefitinib and nimotuzumab in patients with advanced non-small cell lung cancer (NSCLC)
    Kim, Se Hyun
    Shim, Hyo Sup
    Cho, Jaeho
    Jeong, Jae Heon
    Kim, Sun Mi
    Hong, Yun Kyoung
    Sung, Ji Hee
    Ha, Sang-Jun
    Kim, Hye Ryun
    Chang, Hyun
    Kim, Joo Hang
    Tania, Crombet
    Cho, Byoung Chul
    LUNG CANCER, 2013, 79 (03) : 270 - 275
  • [45] A phase I trial of gefitinib and nimotuzumab in patients with advanced non-small cell lung cancer (NSCLC).
    Kim, Han Sang
    Cho, Byoung Chul
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [46] Stereotactic Ablative Radiotherapy for stage I non-small cell lung cancer: retrospective observational study
    Pieri, M.
    Cima, S.
    Capuccini, J.
    Labropoulos, F.
    Palombarini, M.
    Salvi, F.
    Compagnone, G.
    Deodato, F.
    Morganti, A. G.
    Frezza, G.
    RADIOTHERAPY AND ONCOLOGY, 2015, 115 : S636 - S636
  • [47] Gemcitabine combined with cisplatin in non-small cell lung cancer (NSCLC): A phase I/II study
    Steward, WP
    Dunlop, DJ
    Cameron, C
    Talbot, DC
    Kleisbauer, JL
    Thomas, P
    Guerin, JC
    Perol, M
    Sanson, C
    Dabouis, G
    Lacroix, H
    EUROPEAN JOURNAL OF CANCER, 1995, 31A : 1081 - 1081
  • [48] A phase I pharmacokinetic study of bexarotene with paclitaxel and carboplatin in patients with advanced non-small cell lung cancer (NSCLC)
    Jordi Rodon
    Charlotte D. Jacobs
    Quincy Chu
    Eric K. Rowinsky
    Arturo Lopez-Anaya
    Chris H. Takimoto
    Heather A. Wakelee
    Cancer Chemotherapy and Pharmacology, 2012, 69 : 825 - 834
  • [49] Phase I/II study of exisulind and gemcitabine in patients with recurrent advanced non-small cell lung cancer (NSCLC).
    Hoang, T
    Kim, K
    Merchant, J
    Traynor, AM
    Ahuja, HG
    Masters, GA
    McGovern, JD
    Oettel, KR
    Sanchez, FA
    Schiller, JH
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 642S - 642S
  • [50] A phase I pharmacokinetic study of bexarotene with paclitaxel and carboplatin in patients with advanced non-small cell lung cancer (NSCLC)
    Rodon, Jordi
    Jacobs, Charlotte D.
    Chu, Quincy
    Rowinsky, Eric K.
    Lopez-Anaya, Arturo
    Takimoto, Chris H.
    Wakelee, Heather A.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 69 (03) : 825 - 834
12345